Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device

ECLIPSE Trial - Ensure's Vascular Closure Device Speeds Hemostasis Trial

The purpose of this study is to determine whether the Ensure Medical Vascular Closure Device is more effective than standard manual compression at sealing the puncture made in the femoral artery following a cardiac or peripheral diagnostic or interventional procedure while maintaining the same level of safety.

Study Overview

• Status: Completed
• Conditions: Coronary Arteriosclerosis; Angioplasty, Transluminal, Percutaneous Coronary; Peripheral Arteriosclerosis
• Intervention / Treatment: Other: Manual Compression; Device: Vascular Closure Device

Detailed Description

Achieving hemostasis at the arterial puncture site after percutaneous cardiac catheterization is a potential cause of bleeding, hematomas, pseudoaneurysms, and various other vascular complications. Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression or the deployment of a vascular closure device. Manual compression is time consuming for the health-care provider, and painful for the patient. In addition, prolonged periods of immobilization and bed rest may be required. Vascular closure devices have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.

The Ensure Medical Vascular Closure device (VCD) is intended for femoral artery puncture site closure in patients who have undergone coronary or peripheral diagnostic or interventional procedure using a standard 6F introducer sheath. The device is comprised of a bio-absorbable plug and a plug delivery system. The plug delivery system is designed to position the bio-absorbable plug to the extravascular surface of the femoral artery access site, facilitating a hemostasis response. The Ensure Medical VCD has been studied in a prior feasibility trial of 149 patients, which demonstrated that: (1) the device could be used to successfully obtain rapid hemostasis and early ambulation in patients undergoing catheterization procedures; and (2) the low incidence and relatively minor nature of the observed closure related complications suggests that the device is safe for its intended purpose.

The ECLIPSE Trial is designed to evaluate the safety and effectiveness of the Ensure Medical VCD in comparison to standard manual compression. Patients will be randomly assigned to have their arterial access site closed using either manual compression or the VCD. The principal comparisons of the two closure techniques will include:

• Time required to obtain hemostasis of the vascular access site
• Time required for the patient to ambulate after their catheterization
• Frequency of occurrence of serious closure-related complications

• Study Type: Interventional
• Enrollment (Actual): 488
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85054
      • Mayo Clinic Hospital
  • California
    • Sacramento, California, United States, 95817
      • University of California Davis Medical Center
    • Sacramento, California, United States, 95819
      • Sutter Memorial Hospital
    • Stanford, California, United States, 94305-5218
      • Stanford University
  • Florida
    • Clearwater, Florida, United States, 33756
      • Morton Plant Hosptial
  • Indiana
    • Indianapolis, Indiana, United States, 46290
      • The Care Group
  • Missouri
    • St. Louis, Missouri, United States, 63110
      • Washington University School of Medicine at Barnes-Jewish Hospital
  • New Jersey
    • Camden, New Jersey, United States, 08103
      • Cooper Health Systems
  • New York
    • Liverpool, New York, United States, 13088
      • SJH Cardiology Associates
    • New York, New York, United States, 10021
      • New York Presbyterian Hospital - Cornell Medical College of Cornell University
  • North Carolina
    • Raleigh, North Carolina, United States, 27610
      • Wake Heart Research
  • Ohio
    • Cleveland, Ohio, United States, 44122
      • University Hospitals of Cleveland
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19102
      • Hahnemann Hospital
    • Wormleysburg, Pennsylvania, United States, 17043
      • Moffitt Heart & Vascular Group
  • Texas
    • Dallas, Texas, United States, 75226
      • Baylor Research Institute
  • Utah
    • Salt Lake City, Utah, United States, 84143
      • LDS Hospital
  • Washington
    • Seattle, Washington, United States, 98117
      • Swedish Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Scheduled for a coronary or peripheral diagnostic or interventional procedure
• Able to undergo emergent vascular surgery if a complication requires it
• 6F arterial puncture located in the common femoral artery
• Femoral artery has a lumen diameter of at least 5 mm

Exclusion Criteria:

• Arterial puncture in the femoral artery of both legs
• Prior target artery closure with any vascular closure device, or closure with manual compression within 30 days prior to catheterization
• Patients who bruise or bleed easily or with a history of significant bleeding or platelet disorders
• Acute ST-elevation myocardial infarction within 48 hours prior to catheterization
• Uncontrolled hypertension at time of vessel closure
• Elevated Activated Clotting Time at time of vessel closure
• Ineligible for in-catheterization lab introducer sheath removal
• Concurrent participation in another investigational device or drug trial
• Thrombolytic therapy, bivalirudin, other thrombin-specific anticoagulants, or low molecular weight heparin within 24 hours prior to catheterization
• Preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the vessel access site prior to femoral artery closure
• Prior femoral vascular surgery or vascular graft in region of access site
• Femoral artery is tortuous or requires an introducer sheath longer than 11 cm
• Fluoroscopically visible calcium, atherosclerotic disease, or stent within 1 cm of the puncture site that would interfere with the operation of the experimental device
• Difficulty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial puncture
• Antegrade vascular puncture
• Body Mass Index over 40 kg/m^2
• Symptomatic leg ischemia in the target limb including severe claudication or weak/absent pulse
• Femoral artery diameter stenosis exceeding 50%
• Pre-existing severe non-cardiac systemic disease or terminal illness
• Planned arterial access at the same access site within 30 days of catheterization
• Extended hospitalization (e.g. Coronary Artery Bypass Graft (CABG) surgery)
• Pre-existing systemic or cutaneous infection
• Prior use of an intra-aortic balloon pump through the arterial access site
• Cardiogenic shock during or immediately following the catheterization
• Patient is unable to ambulate at baseline
• Patient is known or suspected to be pregnant or is lactating
• Patient is unavailable for follow-up
• Any angiographic or clinical evidence that the physician feels would place the patient at increased risk with the use of the experimental device

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Manual Compression; Manual compression (MC)	Other: Manual Compression; Manual compression
EXPERIMENTAL: Vascular Closure Device; Vascular Closure Device (VCD)	Device: Vascular Closure Device; Investigational vascular closure device; Other Names: Exoseal

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Hemostasis (TTH)	Time to hemostasis is defined as time (in minutes) from when the introducer sheath was removed to the time that hemostasis was first observed during post-procedure follow up. Hemostasis is defined as no or minimal subcutaneous oozing and the absence of expanding or developing hematoma. Time to hemostasis is one of the two co-primary endpoints.	From when the introducer sheath was removed to the time hemostasis was first observed
Time to Ambulation (TTA)	Time to ambulation is defined as the time from when the introducer sheath was removed to the time that ambulation was achieved. Ambulation is defined as patient standing and walking at least 20 feet without re-bleeding or significant oozing requiring manual compression. Time to ambulation is one of the two co-primary endpoints.	From when the introducer sheath was removed to 30 days post-procedure
Percentage of Patients Who Experience Any Vascular Closure Related Major Adverse Events During the 30 Days Post-procedure	Vascular closure related major adverse events consist of any of the events below: Vascular repair or the need for repair; access site-related bleeding requiring transfusion; access site-related infection requiring intravenous/intramuscular antibiotics and/or extended hospitalization; any new ipsilateral lower extremity ischemia documented by symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram; surgery for access site-related nerve injury; and Permanent (> 30 days) access site-related nerve injury.	From post-procedure to 30 days follow up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Eligibility for Hospital Discharge	Time to Eligibility for Hospital Discharge is measured from the time of sheath removal to the time when the patient is eligible for discharge according to the judgment of the patient's physician.	From introducer sheath removal to hospital discharge, up to 284 hours
Time to Hospital Discharge	Time to hospital discharge is defined as from the time of sheath removal to the time of hospital discharge	From introducer sheath removal to patient discharge
Time to Device Deployment, up to 5 Minutes	Time to device deployment is defined as from the time device inserted to the time sheath removed	From device inserted to introducer sheath removal
Percentage of Patients Who Achieved Device Success Within Five Minutes Post-procedure	Device Success is defined as the successful deployment of the plug, initial hemostasis time less or equal to 5 minutes, and removal of the intact delivery system.	Within 5 minutes post-procedure
Percent of Patients Who Achieved Procedure Success During 30 Days Post-procedure	Procedure success is defined as initial hemostasis achieved by the assigned method Vascular Closure Device (VCD) or Manual compression (MC) with none of the primary safety endpoint's closure related major adverse events (MAE). Procedural success is assessed on day of catheterization procedure and at 30 days post-procedure.	From catheterization procedure to 30 day post-procedure follow up
Percentage of Patients Who Experienced Any Other Vascular Closure Related Adverse Events	Other known vascular closure related adverse events include: Rebleeding Following Initial Hemostasis; Access Site Hematoma >= 6cm; Access Site-Related Bleeding Requiring > 30 min for Hemostasis; Transient Access Site-Related Nerve Injury; Retroperitonea Bleeding; Decrease in Pedal Pulse	From end of vessel closure procedure to 30 days post-procedure

Collaborators and Investigators

• Sponsor: Cordis Corporation
• Investigators: Principal Investigator: S. Chiu Wong, MD, New York Presbyterian Hospital

Publications and helpful links

General Publications

• Wong SC, Bachinsky W, Cambier P, Stoler R, Aji J, Rogers JH, Hermiller J, Nair R, Hutman H, Wang H; ECLIPSE Trial Investigators. A randomized comparison of a novel bioabsorbable vascular closure device versus manual compression in the achievement of hemostasis after percutaneous femoral procedures: the ECLIPSE (Ensure's Vascular Closure Device Speeds Hemostasis Trial). JACC Cardiovasc Interv. 2009 Aug;2(8):785-93. doi: 10.1016/j.jcin.2009.06.006.

Study record dates

Study Major Dates

• Study Start: February 1, 2007
• Study Completion (ACTUAL): September 1, 2007

Study Registration Dates

• First Submitted: June 26, 2006
• First Submitted That Met QC Criteria: June 26, 2006
• First Posted (ESTIMATE): June 28, 2006

Study Record Updates

• Last Update Posted (ESTIMATE): June 1, 2012
• Last Update Submitted That Met QC Criteria: May 25, 2012
• Last Verified: May 1, 2012

More Information

Terms related to this study

• Keywords: Hemostasis; Angioplasty; Angiography; Closure Device; Heart Catheterization; Coronary Angiography; Vascular Closure; Peripheral Angiography; Femoral Closure
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arterial Occlusive Diseases; Coronary Disease; Coronary Artery Disease; Myocardial Ischemia; Arteriosclerosis
• Other Study ID Numbers: EM0501